Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.12 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: xl-228, ruserontinib, ponatinib +24 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 9 Parkinson's papers of 4,882 | 0.70 |
| pathways Reactome | 13 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 2321
Sealed predictions
- ABL1 in dopamine neurons, braak-0.29 (p 0.450) → +0.50 (p 0.168)receipt 2327
Swarm cases
receipt 2327: ABL1 in dopamine neurons, braak
- power
- full sample +0.03 (p 0.898, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.962, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.03 (p 0.915, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.18, sign flips 5; without severely affected donors +0.03 (p 0.898, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ABL1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts